Adicet Bio Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters10-31

<a href="https://laohu8.com/S/ACET">Adicet Bio</a> Inc <acet.oq> expected to post a loss of 29 cents a share - Earnings Preview </acet.oq>

Adicet Bio Inc ACET.OQ ACET.O is expected to show no change in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Adicet Bio Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Adicet Bio Inc is $6.50, about 88% above its last closing price of $0.78

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Jun. 30 2025	-0.31	-0.30	-0.34	Missed	-11.7
Mar. 31 2025	-0.33	-0.33	-0.31	Beat	6.5
Dec. 31 2024	-0.36	-0.36	-0.32	Beat	11.6
Sep. 30 2024	-0.35	-0.34	-0.34	Met	0.1
Jun. 30 2024	-0.36	-0.36	-0.33	Beat	9.3
Mar. 31 2024	-0.38	-0.39	-0.35	Beat	9.7
Dec. 31 2023	-0.72	-0.69	-0.69	Met	0.6
Sep. 30 2023	-0.78	-0.74	-1.16	Missed	-57.3

This summary was machine generated October 31 at 11:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579816465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579816465","market":"fut","top_or_hot":-1,"title":"Adicet Bio Inc  expected to post a loss of 29 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ACET\">Adicet Bio</a> Inc <acet.oq> expected to post a loss of 29 cents a share - Earnings Preview </acet.oq></title></head><body><ul><li><p>Adicet Bio Inc <span>ACET.OQ</span> <span>ACET.O</span> is expected to  show no change in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Adicet Bio Inc is for a loss of 29 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Adicet Bio Inc is $6.50, about 88% above its last closing price of $0.78</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-0.31</p></td><td><p>-0.30</p></td><td><p>-0.34</p></td><td><p>Missed</p></td><td><p>-11.7</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-0.33</p></td><td><p>-0.33</p></td><td><p>-0.31</p></td><td><p>Beat</p></td><td><p>6.5</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-0.36</p></td><td><p>-0.36</p></td><td><p>-0.32</p></td><td><p>Beat</p></td><td><p>11.6</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.35</p></td><td><p>-0.34</p></td><td><p>-0.34</p></td><td><p>Met</p></td><td><p>0.1</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.36</p></td><td><p>-0.36</p></td><td><p>-0.33</p></td><td><p>Beat</p></td><td><p>9.3</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-0.38</p></td><td><p>-0.39</p></td><td><p>-0.35</p></td><td><p>Beat</p></td><td><p>9.7</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-0.72</p></td><td><p>-0.69</p></td><td><p>-0.69</p></td><td><p>Met</p></td><td><p>0.6</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-0.78</p></td><td><p>-0.74</p></td><td><p>-1.16</p></td><td><p>Missed</p></td><td><p>-57.3</p></td></tr></tbody></table><p>This summary was machine generated October 31 at 11:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adicet Bio Inc  expected to post a loss of 29 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdicet Bio Inc  expected to post a loss of 29 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ACET\">Adicet Bio</a> Inc <acet.oq> expected to post a loss of 29 cents a share - Earnings Preview </acet.oq></title></head><body><ul><li><p>Adicet Bio Inc <span>ACET.OQ</span> <span>ACET.O</span> is expected to  show no change in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Adicet Bio Inc is for a loss of 29 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Adicet Bio Inc is $6.50, about 88% above its last closing price of $0.78</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-0.31</p></td><td><p>-0.30</p></td><td><p>-0.34</p></td><td><p>Missed</p></td><td><p>-11.7</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-0.33</p></td><td><p>-0.33</p></td><td><p>-0.31</p></td><td><p>Beat</p></td><td><p>6.5</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-0.36</p></td><td><p>-0.36</p></td><td><p>-0.32</p></td><td><p>Beat</p></td><td><p>11.6</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.35</p></td><td><p>-0.34</p></td><td><p>-0.34</p></td><td><p>Met</p></td><td><p>0.1</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.36</p></td><td><p>-0.36</p></td><td><p>-0.33</p></td><td><p>Beat</p></td><td><p>9.3</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-0.38</p></td><td><p>-0.39</p></td><td><p>-0.35</p></td><td><p>Beat</p></td><td><p>9.7</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-0.72</p></td><td><p>-0.69</p></td><td><p>-0.69</p></td><td><p>Met</p></td><td><p>0.6</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-0.78</p></td><td><p>-0.74</p></td><td><p>-1.16</p></td><td><p>Missed</p></td><td><p>-57.3</p></td></tr></tbody></table><p>This summary was machine generated October 31 at 11:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACET","symbol_name":"艾切托","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC10G:1","article_id":"2579816465","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579816465","pubTimestamp":1761909965,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adicet Bio Inc  expected to post a loss of29cents a share - Earnings Preview Adicet Bio Inc ACET.OQ ACET.O is expected to  show no change in quarterly revenue when it reports  results on November 4 (e","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACET":"艾切托","BK4139":"生物科技"},"translate_title":"Adicet Bio Inc预计每股亏损29美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACET":0.9},"content_text":"Adicet Bio Inc  expected to post a loss of 29 cents a share - Earnings Preview Adicet Bio Inc ACET.OQ ACET.O is expected to  show no change in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2025LSEG's mean analyst estimate for Adicet Bio Inc is for a loss of 29 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Adicet Bio Inc is $6.50, about 88% above its last closing price of $0.78Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Jun. 30 2025-0.31-0.30-0.34Missed-11.7Mar. 31 2025-0.33-0.33-0.31Beat6.5Dec. 31 2024-0.36-0.36-0.32Beat11.6Sep. 30 2024-0.35-0.34-0.34Met0.1Jun. 30 2024-0.36-0.36-0.33Beat9.3Mar. 31 2024-0.38-0.39-0.35Beat9.7Dec. 31 2023-0.72-0.69-0.69Met0.6Sep. 30 2023-0.78-0.74-1.16Missed-57.3This summary was machine generated October 31 at 11:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579816465","isCrawlerRequest":true}